Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lucentis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

Regeneron and Bayer drop AMD combination

Regeneron and Bayer drop AMD combination Novartis does have to be wary of cannibalising sales of its established AMD therapy Lucentis (ranibizumab), which is playing second fiddle to Eylea but is still a blockbuster – albeit one headed

NICE first fast-track appraisal backs Bayer's Eylea

NICE first fast-track appraisal backs Bayer's Eylea will compete against Novartis’ already NICE-recommended Lucentis ( ranibizumab).

A new decade of disruption: meeting the biosimilar challgenge

A new decade of disruption: meeting the biosimilar challgenge As the dust settles on the first ten years of disruption, the spotlight is now on the future as more leading MAbs, including Humira (adalimumab), MabThera (rituximab), Avastin (bevacizumab) and Lucentis

Promoting off-label use: where to draw the line?

Promoting off-label use: where to draw the line? Such an approach would also harm innovation. While the report often cites Lucentis and Avastin as examples of the perceived issue (with some remarks about the drugs' common origin), it does

Novartis' AMD drug pegpleranib fails phase III programme

Novartis' AMD drug pegpleranib fails phase III programme Plans for Lucentis-boosting duel-therapy stumble as trial data show no additional benefit. ... or wet forms of AMD provided no additional benefit over Lucentis given alone.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...
APAC map
Pharmaceutical innovation in the APAC region
A first-of-its-kind study paints a vivid picture of the APAC region’s future...
Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...

Infographics